The N-methyl-D-aspartate (NMDA) 1 subtype of ionotropic glutamate receptor plays a major role in physiological (longterm synaptic plasticity) and pathological (epilepsy, excitotoxicity in stroke) processes in the brain (1). NMDA receptors function as heteromeric assemblies composed of glycine-binding NR1 subunits in combination with at least one type of glutamate-binding NR2 subunit (2-4). NMDA receptors have three transmembrane domains (M1, M3, and M4) plus a cytoplasmic re-entrant membrane loop (M2) (5). Contained within the M3 transmembrane domain is the motif with the strictest amino acid conservation (SYTANLAAF, Fig. 1) among all the members of the ionotropic glutamate receptor family, indicating an important role in channel function (6 -8). In the naturally occurring lurcher mutant mice, GluR␦2 receptors contain an alanine to threonine mutation in this motif (9). The lurcher mice suffer cerebellar degeneration resulting in ataxia and impaired motor learning. Introducing the analogous lurcher mutation into NR1, GluR1, or GluR6 receptors decreases agonist EC 50 values and/or decreases the rate of receptor deactivation (10 -12). This suggests that transmembrane domain M3 may play a critical role in the channel gating of ionotropic glutamate receptors. Jones et al. (13) reported that replacement of the alanine at position 7 of the SYTANLAAF motif of NR1 or NR2A with cysteine (hereafter A7C) produced agonistinduced accessibility changes for sulfhydryl-modifying reagents. This residue was susceptible to covalent modification by extracellular MTSEA only when it was co-applied during channel activation by glutamate and glycine, suggesting that a change in solvent accessibility of this residue is associated with channel activation. MTSEA modification dramatically slowed the deactivation of the mutated NMDA receptors, indicating that M3 functions as a transduction element whose conformational change couples ligand binding with channel opening. Here we demonstrate that this role for M3 is conserved not only between NR1 and NR2A, but also for NR2B, NR2C, and NR2D. The MTSEA modification of the mutation A7C on NR1, NR2A, NR2B, NR2C, or NR2D potentiates currents to a varying degree depending on the identity of the NR2 subunit, and the MTSEA-modified channels remain open even following removal of glutamate and glycine from the external solution. These modified channels are insensitive to competitive NMDA antagonists (APV and 7-Cl-kynurenic acid) and allosteric modulators of gating (low pH and Zn 2ϩ ). MTSEA-modified channels are inhibited by channel blockers (Mg 2ϩ , (ϩ)MK-801, (Ϫ)MK-801, ketamine, memantine, amantadine, dextrorphan), although divergent effects for some of these blockers were observed in the absence or presence of the agonists. We interpret these results as evidence that the M3 transmembrane domain plays a conserved role in channel function for all NMDA subunits.